Notably, there is a significant unmet need in clinical practice if we establish the definition of secondary resistance to immunotherapy alone because chemotherapy plus IO is the mainstream treatment option for metastatic NSCLC, especially in patients with PD‐L1 < 50%. The gene discussed is CD274; the disease is non-small cell lung carcinoma.